Forbes April 18, 2022
Rita Numerof

Our firm has been measuring progress along the journey to population health for 7 years. That progress has been painfully slow. While the pandemic did shine a light on why we need a predictable revenue model in healthcare delivery focused on prevention and primary care, bailouts and rescues have kept a dying fee-for-service model on continued life support. Population health represents a real opportunity for providers to improve not only the health and well-being of those they serve, but also their own financial health.

However, and despite general agreement with this outlook among industry insiders, our research highlights that most providers have yet to commit themselves to a new model. Instead, the general theme has been to blame others for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Healthcare System, Pharma, Pharma / Biotech, Population Health Mgmt
11 drugs now in shortage
Scientists reveal new method that could reduce waste from drug manufacturing
ETH develops AI algorithm for drug discovery based on 3D protein surface
Pharma Pulse 4/26/24: 20 States Select Direct Care Workforce Enhancement Programs by HHS, Do Assigned Roles in Clinical Trials Affect Patient-Reported Outcomes? & more
What's 'in vogue' for chief pharmacy officers

Share This Article